{
  "docId": "019de073-e127-72a6-a95e-e417b3ed6013",
  "docSlug": "0a46c3e8bf46013b57087adaac7a88f4",
  "documentTitle": "Xeris Biopharma | Investor Presentation Deck | 11 slides",
  "authorId": "xeris-biopharma",
  "authorName": "Xeris Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 4,
  "pageCount": 11,
  "prevPage": 3,
  "nextPage": 5,
  "slideType": "market_sizing",
  "function": "size_opportunity",
  "density": "overcrowded",
  "nDataPoints": 7,
  "notes": "The slide uses a problem-solution framework to justify the market size for a new delivery method.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-e127-72a6-a95e-e417b3ed6013/4",
  "deckHref": "/decks/019de073-e127-72a6-a95e-e417b3ed6013",
  "deckJsonHref": "/decks/019de073-e127-72a6-a95e-e417b3ed6013.json",
  "deckAnchorHref": "/decks/019de073-e127-72a6-a95e-e417b3ed6013#slide-4",
  "components": [
    {
      "bbox": {
        "h": 0.55,
        "w": 0.4,
        "x": 0.55,
        "y": 0.31
      },
      "kind": "list",
      "text": "105M Rx/yr dispensed; 47% GI condition; 21% concomitant meds; 17% compliance issues; 15% hard to control; 62M weekly doses; $30-$50/dose; $2-3B Opportunity",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "60bbddbd-0b25-4a58-968f-6caedee633e3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.45,
        "x": 0.04,
        "y": 0.45
      },
      "kind": "list",
      "text": "1st injectable levothyroxine indicated for hypothyroidism; Bypasses GI tract; Improved regimen compliance; Demonstrate safety; Small volume, ready-to-use",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7fd86a93-3356-4bae-97d3-814afae84507",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.45,
        "x": 0.04,
        "y": 0.31
      },
      "kind": "paragraph",
      "text": "XP-8121 — Levothyroxine. For maintenance therapy in patients with congenital or acquired hypothyroidism who require thyroid hormone replacement",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "115ef5e5-86a8-4510-9801-d0ce71d24440",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.04,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "Sources: 1. IQVIA NPA Y2021; 2. McMillan M et al. Drugs R D. 2016 16(1):53-68; 3. Robertson HM et al Thyroid : Official Journal of the American Thyroid Association. 2014 24(12):1765-1771. 4. Tirosint WAC and 5x premium to Synthroid",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "34d8bd06-453a-4e34-a6f0-e1a669b4636b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.92,
        "x": 0.04,
        "y": 0.21
      },
      "kind": "title",
      "text": "With over 100M Rx/yr, oral levothyroxine is one of the most prescribed therapies in US",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e34fe21d-59f8-4eef-84ea-3605e171d66b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.92,
        "x": 0.04,
        "y": 0.12
      },
      "kind": "title",
      "text": "XeriSol™ Levothyroxine may enable 1x/weekly subcutaneous (SC) therapy",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "842f6723-afa8-4932-b73e-e40675387b34",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Market Segmentation Pyramid",
      "slug": "market-segmentation-pyramid",
      "agent": null,
      "layer": "slide",
      "matchId": "631d0e42-5cea-4e04-ab4a-dd7c591d5d1e",
      "evidence": "list/bullet: 105M Rx/yr dispensed; 47% GI condition; 21% concomitant meds; 17% compliance issues; 15% hard to control; 62M weekly doses; $30-$50/dose; $2-3B Opportunity",
      "confidence": 0.6
    }
  ],
  "frameworks": [
    {
      "name": "market-sizing",
      "slug": null,
      "matchId": "1d18db4f-b668-4608-9afe-149137e5367a",
      "evidence": "Quantifies total addressable market and specific segments based on clinical pain points.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 4,
      "from": 4,
      "beatId": "1cb39058-49a4-4f20-ad7f-4e5ca72f0e60",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Problem",
      "beatSlug": "sequoia-pitch-problem",
      "evidence": "The market sizing slide presents the problem and opportunity.",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 4,
      "from": 4,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "bc2291b6-982f-4de3-9315-7a84eb9dc296",
      "evidence": "The market sizing slide implies the cost of inaction.",
      "position": 0,
      "objective": "What are the limitations of current Levothyroxine therapies?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}